3R Pharma Ltd. Announces the Appointment of Prof. Boris Knaizer to its Scientific Advisory Board

June 22, 2023 – Yeruham, Israel: 3R Pharma Ltd., a preclinical-stage pharmaceutical company focused on developing novel cannabinoid-based therapies for ophthalmic diseases, today announced the appointment of Prof. Boris Knaizer to its Scientific Advisory Board (SAB). Prof. Knaizer will bring clinical leadership and scientific insight to guide the company’s ophthalmic drug development programs.

Prof. Knaizer currently serves as Head of the Cornea and Corneal Transplantation Unit and is the Acting Head of the Ophthalmology Department at Soroka Medical Center. He is also an Associate Professor of Ophthalmology at Ben-Gurion University, with extensive experience in ocular surface disease, corneal pathology, and translational research.

Michael Rubinov, CEO of 3R Pharma, stated: “We are honored to have Prof. Knaizer join our Scientific Advisory Board. His clinical expertise in ocular surface disorders and his deep understanding of translational medicine will be critical as we advance our lead cannabinoid-based candidates. His involvement strengthens our ability to make sound scientific decisions and accelerate progress toward the clinic.”

Prof. Boris Knaizer commented: “It’s a privilege to join 3R Pharma’s SAB and support the development of novel therapies for patients with chronic eye conditions like Dry Eye disease. The company’s science is compelling, and its focus on cannabinoid-based innovation in ophthalmology is both timely and promising. I look forward to collaborating with the team to translate this innovation into meaningful clinical outcomes.”

About 3R Pharma Ltd

3R Pharma is a Yeruham-based pharmaceutical technology company developing cannabinoid-based therapies for ocular surface diseases, including Dry Eye disease. The company’s pipeline includes several preclinical candidates targeting inflammation and unmet medical needs in ophthalmology. 3R Pharma is part of the CanNegev Start-Up Incubator and is supported by the Israeli Innovation Authority.

Media Contact:

Eden Chen eden@3rpharma.com Israel:    +972-544-742750 USA:      +1201-781- 2959 www.3Rpharma.com